[HTML] springer.com

[HTML][HTML] Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

D Guermazi, P Arvanitis, D Farmakiotis - Infection, 2023 - Springer
We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …
被引用次数：3 相关文章
[HTML] nih.gov

[HTML][HTML] Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

D Guermazi, P Arvanitis, D Farmakiotis - Infection - ncbi.nlm.nih.gov
We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …
[PDF] researchgate.net

[PDF][PDF] Molnupiravir efficacy among immunocompromised patients with COVID‑19: no proof of concept

D Guermazi, P Arvanitis, D Farmakiotis - Infection, 2023 - researchgate.net
We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …

Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept.

D Guermazi, P Arvanitis, D Farmakiotis - Infection, 2023 - europepmc.org
We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …

[引用][C] Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of concept

D Guermazi, P Arvanitis, D Farmakiotis - Infection, 2023 - pubmed.ncbi.nlm.nih.gov
Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof of
concept Molnupiravir efficacy among immunocompromised patients with COVID-19: no proof …